Remembering
Stanford L. Kurland
Stanford L. Kurland began his professional career in public accounting in 1975 at Grant Thorton, formerly known as Alexander Grant. One of his early assignments was at a mortgage bank called Countrywide Credit Industries and its operating subsidiary Countrywide Acceptance Company. Stan’s skills were quickly observed by Countrywide’s founders and he joined the organization in 1979. It didn’t take long for Stan to help Countrywide change the non-bank mortgage banking industry and over an almost 30-year career at Countrywide, he served as Chief Operating Officer, Chief Financial Officer, President and Director of the public company.
In 2008, Stan founded and led Pennymac Financial Services, Inc. and Pennymac Mortgage Investment Trust — now considered one of the premiere non-bank mortgage enterprises in America. At Pennymac, Stan was the Chairman and Chief Executive Officer of two NYSE-listed companies until his retirement at the end of 2019.
In early 2020, Stan was diagnosed with an inoperable brain tumor and began treatment at UCLA. Stan was fortunate to be in such good care until his passing in January 2021.
Despite the discomfort of radiation and chemotherapy, Stan was determined to help cure an “incurable” disease and lessen the distress of treatment for others. His work and legacy live on through this event that honors his memory and tireless philanthropy.
Please join us in this noble endeavor by giving directly to the UCLA Neuro-Oncology Program at giving.ucla.edu/StanfordKurland or by becoming a sponsor of this year’s Stanford L. Kurland Memorial Golf Classic benefiting the UCLA Neuro-Oncology Program.
UCLA Neuro-Oncology Program
Timothy Cloughesy, M.D., Director of the UCLA Neuro-Oncology Program and Professor of Clinical Neurology, and David Nathanson, Ph.D., Professor of Molecular and Medical Pharmacology at UCLA, lead the research and development effort that already has made a powerful impact in battling the disease.
Thanks to the millions of dollars already raised by the Stanford L. Kurland Research Fund, UCLA NeuroOncology has made significant strides:
- Unprecedented results from clinical trials of the KTM-101 drug developed at UCLA show that it halted tumor growth for at least 6 months in over one-third of patients.
- A new drug developed takes down cancer cell defenses that have repelled traditional therapies in the past.
- Groundbreaking discoveries are fueling next-generation therapies that bring in immunotherapy and combination therapies, projected to drive exponential advancement toward a cure.
